Bezafibrate
Bezafibrate is a small molecule pharmaceutical. It is currently being investigated in clinical studies. The pharmaceutical is active against peroxisome proliferator-activated receptor alpha.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
25 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hypercholesterolemia | D006937 | HP_0003124 | — | — | — | 1 | 1 | — | 2 |
| Syndrome | D013577 | — | — | — | 1 | — | 1 | — | 2 |
| Metabolic diseases | D008659 | EFO_0000589 | E88.9 | — | — | — | 1 | 1 | 2 |
| Acute coronary syndrome | D054058 | EFO_0005672 | — | — | — | — | 1 | — | 1 |
| Coronary artery disease | D003324 | — | I25.1 | — | — | — | 1 | — | 1 |
| Myocardial ischemia | D017202 | EFO_1001375 | I20-I25 | — | — | — | 1 | — | 1 |
| Atherosclerotic plaque | D058226 | HP_0031678 | I70 | — | — | — | 1 | — | 1 |
| Muscular diseases | D009135 | HP_0003198 | G72.9 | — | — | — | 1 | — | 1 |
| Congenital ichthyosiform erythroderma | D016113 | — | — | — | — | — | 1 | — | 1 |
| Lipidoses | D008064 | — | E75.6 | — | — | — | 1 | — | 1 |
Show 4 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Biliary liver cirrhosis | D008105 | — | K74.3 | — | 2 | 6 | — | 1 | 9 |
| Cholangitis | D002761 | HP_0030151 | K83.0 | — | 2 | 5 | — | 1 | 8 |
| Sclerosing cholangitis | D015209 | EFO_0004268 | K83.01 | — | — | 2 | — | — | 2 |
| Optic nerve diseases | D009901 | EFO_1001330 | H47.14 | — | 1 | 1 | — | — | 1 |
| Hereditary optic atrophy leber | D029242 | Orphanet_104 | H47.22 | — | 1 | 1 | — | — | 1 |
| Self efficacy | D020377 | — | — | — | 1 | 1 | — | — | 1 |
| Healthy volunteers/patients | — | — | — | — | 1 | 1 | — | — | 1 |
| Inborn errors metabolism | D008661 | — | — | — | — | 1 | — | — | 1 |
| Cholestasis | D002779 | HP_0001396 | K83.1 | — | — | 1 | — | — | 1 |
| Liver cirrhosis | D008103 | EFO_0001422 | K74.0 | — | — | 1 | — | — | 1 |
Show 2 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | — | 1 | — | — | — | 1 |
| Diabetes mellitus | D003920 | HP_0000819 | E08-E13 | — | 1 | — | — | — | 1 |
| Depression | D003863 | — | F33.9 | — | 1 | — | — | — | 1 |
| Bipolar disorder | D001714 | EFO_0000289 | F30.9 | — | 1 | — | — | — | 1 |
| Mitochondrial diseases | D028361 | EFO_0000591 | — | — | 1 | — | — | — | 1 |
| Mitochondrial myopathies | D017240 | Orphanet_206966 | G71.3 | — | 1 | — | — | — | 1 |
| Hemophilia b | D002836 | — | D67 | — | 1 | — | — | — | 1 |
| Multiple acyl coenzyme a dehydrogenase deficiency | D054069 | — | E71.313 | — | 1 | — | — | — | 1 |
| Myelodysplastic syndromes | D009190 | — | D46 | — | 1 | — | — | — | 1 |
| Preleukemia | D011289 | — | — | — | 1 | — | — | — | 1 |
Indications Phases 1
No data
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hypertriglyceridemia | D015228 | EFO_0004211 | — | — | — | — | — | 1 | 1 |
| Adrenoleukodystrophy | D000326 | Orphanet_43 | E71.52 | — | — | — | — | 1 | 1 |
| Glucose metabolism disorders | D044882 | — | — | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Bezafibrate |
| INN | bezafibrate |
| Description | Bezafibrate is a monocarboxylic acid amide obtained by the formal condensation of the carboxy group of 4-chlorobenzoic acid with the amino group of 2-[4-(2-aminoethyl)phenoxy]-2-methylpropanoic acid. Benafibrate is used for the treatment of hyperlipidaemia. It has a role as a xenobiotic, an environmental contaminant, a geroprotector and an antilipemic drug. It is a monocarboxylic acid, an aromatic ether, a member of monochlorobenzenes and a monocarboxylic acid amide. It is functionally related to a propionic acid. |
| Classification | Small molecule |
| Drug class | antihyperlipidemics (clofibrate type) |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CC(C)(Oc1ccc(CCNC(=O)c2ccc(Cl)cc2)cc1)C(=O)O |
Identifiers
| PDB | — |
| CAS-ID | 41859-67-0 |
| RxCUI | — |
| ChEMBL ID | CHEMBL264374 |
| ChEBI ID | 47612 |
| PubChem CID | 39042 |
| DrugBank | DB01393 |
| UNII ID | Y9449Q51XH (ChemIDplus, GSRS) |
Target
Agency Approved
PPARA
PPARA
Organism
Homo sapiens
Gene name
PPARA
Gene synonyms
NR1C1, PPAR
NCBI Gene ID
Protein name
peroxisome proliferator-activated receptor alpha
Protein synonyms
Nuclear receptor subfamily 1 group C member 1, peroxisome proliferative activated receptor, alpha
Uniprot ID
Mouse ortholog
Ppara (19013)
peroxisome proliferator-activated receptor alpha (P23204)
Alternate
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 4,487 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
535 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use